vistagen(vtgn):孕期養生心得
孕期養生心得描述::Vistagen(VTGN):
Vistagen(VTGN) PRE 14A Other preliminary proxy statements Accession Number: 0001851734-22-000475 Act: 34 Size: 898 KB 網頁鏈接
Vistagen(VTGN):
Vistagen(VTGN) DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001851734-22-000518 Act: 34 Size: 580 KB 網頁鏈接
Vistagen(VTGN):
Vistagen(VTGN) 8-K Current report, items 5.03 and 9.01 Accession Number: 0001851734-22-000516 Act: 34 Size: 169 KB 網頁鏈接
Vistagen(VTGN):
Vistagen(VTGN) 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001851734-22-000662 Act: 34 Size: 7 MB 網頁鏈接
Vistagen(VTGN):
Vistagen(VTGN) 8-K Current report, items 8.01 and 9.01 Accession Number: 0001851734-22-000719 Act: 34 Size: 176 KB 網頁鏈接
Vistagen(VTGN):
Vistagen(VTGN) 8-K Current report, items 7.01 and 9.01 Accession Number: 0001851734-22-000699 Act: 34 Size: 3 MB 網頁鏈接
Vistagen(VTGN):
Vistagen(VTGN) 8-K Current report, items 5.07, 7.01, and 9.01 Accession Number: 0001851734-22-000626 Act: 34 Size: 215 KB 網頁鏈接
Vistagen(VTGN):
Vistagen(VTGN) 8-K Current report, items 2.02 and 9.01 Accession Number: 0001851734-22-000663 Act: 34 Size: 305 KB 網頁鏈接
Vistagen(VTGN):
Vistagen(VTGN) 8-K Current report, items 5.02, 8.01, and 9.01 Accession Number: 0001851734-22-000697 Act: 34 Size: 187 KB 網頁鏈接
Vistagen(VTGN):
Vistagen(VTGN) 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-22-008937 Size: 8 KB 網頁鏈接
Vistagen(VTGN):
Vistagen(VTGN) 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-22-008894 Size: 5 KB 網頁鏈接
Vistagen(VTGN):
Vistagen(VTGN) 8-K Current report, item 3.01 Accession Number: 0001851734-22-000545 Act: 34 Size: 157 KB 網頁鏈接
Vistagen(VTGN):
Vistagen(VTGN) 8-K Current report, item 5.07 Accession Number: 0001851734-22-000643 Act: 34 Size: 163 KB 網頁鏈接
美股滾雪球:
Vistagen(VTGN) 將收購專注于神經精神病學和神經內分泌疾病的Pherin Pharmaceuticals。
交易條款要求VTGN以1240萬股普通股以及一些現金支付。
Pherin的最新一期資產是PH94B,處于社交焦慮障礙的3期和焦慮適應障礙的2期發展階段。該公司還將PH10定為重度抑郁癥的2期。
PH10于12月初被美國FDA授予快速通道稱號。長春高新(SZ000661)康泰生物(SZ300601)
Vistagen(VTGN):
Vistagen(VTGN) 8-K Current report, items 8.01 and 9.01 Accession Number: 0001851734-22-000709 Act: 34 Size: 177 KB 網頁鏈接
Vistagen(VTGN):
Vistagen(VTGN) 8-K Current report, items 1.01, 7.01, and 9.01 Accession Number: 0001851734-22-000740 Act: 34 Size: 923 KB 網頁鏈接
Vistagen(VTGN):
Vistagen(VTGN) DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001851734-22-000594 Act: 34 Size: 37 KB 網頁鏈接
Vistagen(VTGN):
Vistagen(VTGN) 8-K Current report, items 8.01 and 9.01 Accession Number: 0001851734-22-000591 Act: 34 Size: 191 KB 網頁鏈接
Vistagen(VTGN):
Vistagen(VTGN) DEF 14A Other definitive proxy statements Accession Number: 0001851734-22-000517 Act: 34 Size: 1 MB 網頁鏈接